
Canopy selling German medical subsidiary
BNN Bloomberg
Canopy Growth Corp. says it has signed a deal to sell its C3 Cannabinoid Compound Company GmbH subsidiary to German company Dermapharm Holding SE.
SMITHS FALLS, ONT. -- Canopy Growth Corp. says it has signed a deal to sell its C3 Cannabinoid Compound Company GmbH subsidiary to German company Dermapharm Holding SE.
Under the agreement, Canopy will receive an upfront payment of $115.5 million.
It will also receive up an additional $61.4 million, subject to the achievement of certain milestones by the business.
Dermapharm is a European pharmaceutical company based in Gruenwald, Germany.
The business being sold develops and manufactures pharmaceutical products and includes Spectrum Therapeutics GmbH, THC Pharm GmbH The Health Concept and Spectrum Therapeutics Austria GmbH.
The deal, which requires regulatory approvals, is expected to close by Jan. 31, 2022 .

U.S. President Donald Trump on Monday said the U.S. was talking with a “respected” Iranian leader and claimed the Islamic Republic was eager for a deal to end the war. He also extended a deadline for Iran to reopen the crucial Strait of Hormuz or face attacks on its power plants, saying it has an additional five days.

Jurors wade through daunting evidence in high-stakes Meta trial about social media risks to children
A stream of testimony and evidence has been presented in a New Mexico case exploring what Meta knew about the effects of its platforms on children.











